Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2019

View Archived Issues

"Love hormone" causes heartbreak -- literally

Improving Imbruvica

Identification of a novel potent EML4-ALK inhibitor for non-small cell lung carcinoma

Inebilizumab demonstrates safety and efficacy in phase III N-MOmentum study

Batavia Biosciences and University of Tokyo to develop a vector-based vaccine against Nipah virus

AMS-0421, an aptamer targeting VEGF-A for retinal disease

Protagonist Therapeutics presents phase I data for PN-943

Tolimidone leads to significant reduction of HbA1c in phase IIb trial in type 2 diabetes

Angex Pharmaceutical identifies indoleamine 2,3-dioxygenase 1 inhibitors

Advent Pharma discovers fibroblast growth factor receptor 4 inhibitors

New vasopressin V1A and V2 receptor antagonists described by Bayer

Hitgen patents histone deacetylase inhibitors

Beijing Yuezhikangtai Biomedicines discloses AXL and/or c-Met inhibitors

Integrator proteins shown to resist nerve cell regression

Flotillin-1/2 as a novel target in patients with CNS inflammatory conditions

AEA, PEA and OEA as promising novel biomarkers for autism spectrum disorder

Alzheimer's candidate PRI-002 completes phase I testing

Precision BioSciences describes ARCUS gene editing strategy for hepatitis B

Mutation in ROBO1 gene tied to development of CPHD

FDA approves Bavencio with Inlyta for advanced renal cell carcinoma

Sanofi doses first patient in phase IIb study of SAR-442168 for relapsing MS

Encouraging phase I data reported for dAd5GNE anti-cocaine vaccine

Sienna reports biopsy data from phase IIb study of SNA-120 for psoriasis

DSMB recommends continuation of phase II study of SENS-111 in acute unilateral vestibulopathy

Allegro reports promising results from proof-of-concept study of ALG-007 in dry eye disease

Phase III study of abrocitinib in atopic dermatitis meets all coprimary and secondary endpoints

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...